Safety and Effectiveness of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer in Real-World Settings: First Observations from an Interdisciplinary Breast Cancer Centre in Germany

    Mattea Reinisch, S. Bruz̆as, Jennifer Spoenlein, Satyendra S. Shenoy, Alexander Traut, Hakima Harrach, Ouafaa Chiari, E. Cremer, Beyhan Ataseven, Lars Gubelt, Sherko Kuemmel
    Studysummary This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →